Skip to main content
profile image
Selected Works of Julia Chapman, MD, FACOG
Article
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Gynecologic Oncology (2010)
  • Gini F. Fleming, University of Chicago
  • Michael W. Sill, University at Buffalo
  • Michael W. Sill, Gynecologic Oncology Group
  • Kathleen M. Darcy, Gynecologic Oncology Group
  • D. Scott McMeekin, University of Oklahoma
  • J. Tate Thigpen, University of Mississippi Medical Center
  • Lisa M. Adler, Anschutz Medical Campus
  • Jonathan S. Berek, University of California, Los Angeles
  • Julia A. Chapman, University of Kansas
  • Paul A. DiSilvestro, Stony Brook University
  • Ira R. Horowitz, Emory University
  • James V. Fiorica, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Link
Disciplines
Publication Date
January 1, 2010
DOI
10.1016/J.YGYNO.2009.09.025
Citation Information
Gini F. Fleming, Michael W. Sill, Michael W. Sill, Kathleen M. Darcy, et al.. "Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study." Gynecologic Oncology Vol. 116 Iss. 1 (2010) p. 15 - 20
Available at: http://works.bepress.com/julia-chapman/19/